Oltipraz in the Prevention of Lung Cancer in People Who Smoke
Completed
National Cancer Institute (NCI)
Phase 1
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the
development of cancer.
PURPOSE: Randomized phase I trial to study the effectiveness of oltipraz in preventing lung
cancer in people who smoke.
Oltipraz in the Prevention of Lung Cancer in People Who Smoke
Completed
Northwestern University
Phase 1
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the
development of cancer.
PURPOSE: Randomized phase I trial to study the effectiveness of oltipraz in preventing lung
cancer in people who smoke.
Efficacy and Safety of Oltipraz in the Patients With Non-alcoholic Fatty Liver Disease
Completed
PharmaKing
Phase 2
Dithiolethiones, a novel class of adenosine monophosphate-activated protein kinase (AMPK)
activators, prevent insulin resistance through AMPK-dependent p70 ribosomal S6 kinase-1
(S6K1) inhibition. And it is well known that the modulation of S6K1 by oltipraz inhibited the
development of insulin resistance and hyperglycemia through the AMPK-S6K1 pathway.Also some
research reported that LXRg (a member of the nuclear hormone receptor)-mediated increases in
SREBP-1c (the sterol regulatory element-binding protein-1c gene) promote the expression of
lipogenic genes and enhance fatty acid synthesis and oltipraz inhibits LXRg and SREBP-c.
Therefore, Oltipraz inhibits fatty acid synthesis through AMPK-S6K1 pathway and LXRg-SREBP-1c
pathway in liver.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
